Solid Biosciences Inc. Debt Securities, Available-for-sale
Solid Biosciences Inc. (SLDB) had Debt Securities, Available-for-sale of $218.28 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale $218.28M.
- 2026-03-31: Debt Securities, Available-for-sale $83.58M.
- 2025-12-31: Debt Securities, Available-for-sale $127.95M.
- 2025-09-30: Debt Securities, Available-for-sale $174.78M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $218.28M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $83.58M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $127.95M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $174.78M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $129.18M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $96.29M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $68.69M 10-K · filed 2026-03-19 |
| 2024-09-30 | $106.72M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $94.41M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $88.49M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $49.63M 10-K · filed 2025-03-06 |
| 2023-09-30 | $93.85M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $68.62M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $20.86M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $58.34M 10-K · filed 2024-03-13 |
| 2022-09-30 | $93.37M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $108.57M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $50.34M 10-Q · filed 2022-04-27 |
| 2021-12-31 | $88.64M 10-K · filed 2023-03-23 |
| 2021-09-30 | $120.08M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $48.35M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-14 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-14 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 |
| 2020-03-31 | $400.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $7.48M 10-K · filed 2021-03-15 |
| 2019-09-30 | $10.94M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $15.55M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $40.75M 10-Q · filed 2019-05-13 |
| 2018-12-31 | $36.10M 10-K · filed 2020-03-12 |
| 2018-09-30 | $16.23M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $16.93M 10-Q · filed 2018-08-10 |
| 2018-03-31 | $17.61M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $17.01M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |